Literature DB >> 22210382

Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3.

Yasuo Harada1, Isao Ishii, Kiyohiko Hatake, Tadashi Kasahara.   

Abstract

Pyrvinium pamoate (PP), a classical anthelminthic, potently inhibited proliferation and STAT3 Tyr705 phosphorylation of human myeloma (U266B1 and PCM6)/erythroleukemia (HEL 92.1.7) cells. PCM6 cell proliferation was markedly impaired by STAT3 siRNA knockdown. PP inhibited ATP production/O(2) consumption in those three cells and mitochondrial respiratory complex (I+III, but not II+III) activity in mouse kidney mitochondrial fractions. PP inhibition of ATP production, STAT3 Tyr705 phosphorylation, and proliferation was absent in mitochondrial DNA-deficient HEL 92.1.7-ρ(0) cells. Moreover, PP acted synergistically with dexamethasone to inhibit PCM6 cell proliferation. In conclusion, we identified PP as a potential anticancer drug directed against mitochondrial respiratory complex I/STAT3.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22210382     DOI: 10.1016/j.canlet.2011.12.034

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  26 in total

1.  The impact of pyrvinium pamoate on colon cancer cell viability.

Authors:  Armin Wiegering; Friedrich-Wilhelm Uthe; Melanie Hüttenrauch; Bettina Mühling; Michael Linnebacher; Franziska Krummenast; Christoph-Thomas Germer; Andreas Thalheimer; Christoph Otto
Journal:  Int J Colorectal Dis       Date:  2014-07-26       Impact factor: 2.571

2.  Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.

Authors:  Sandipan Datta; Thomas Sears; Gino Cortopassi; Kevin Woolard; James M Angelastro
Journal:  Biomed Pharmacother       Date:  2020-12-08       Impact factor: 6.529

3.  Atovaquone enhances doxorubicin's efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer.

Authors:  Zhuo Lv; Xintong Yan; Liying Lu; Chun Su; Yin He
Journal:  J Bioenerg Biomembr       Date:  2018-04-23       Impact factor: 2.945

4.  The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria.

Authors:  Christopher W Schultz; Grace A McCarthy; Teena Nerwal; Avinoam Nevler; James B DuHadaway; Matthew D McCoy; Wei Jiang; Samantha Z Brown; Austin Goetz; Aditi Jain; Valerie S Calvert; Vikalp Vishwakarma; Dezhen Wang; Ranjan Preet; Joel Cassel; Ross Summer; Hoora Shaghaghi; Yves Pommier; Simone A Baechler; Michael J Pishvaian; Talia Golan; Charles J Yeo; Emanuel F Petricoin; George C Prendergast; Joseph Salvino; Pankaj K Singh; Dan A Dixon; Jonathan R Brody
Journal:  Mol Cancer Ther       Date:  2021-08-19       Impact factor: 6.261

5.  Pyrvinium attenuates Hedgehog signaling downstream of smoothened.

Authors:  Bin Li; Dennis Liang Fei; Colin A Flaveny; Nadia Dahmane; Valérie Baubet; Zhiqiang Wang; Feng Bai; Xin-Hai Pei; Jezabel Rodriguez-Blanco; Brian Hang; Darren Orton; Lu Han; Baolin Wang; Anthony J Capobianco; Ethan Lee; David J Robbins
Journal:  Cancer Res       Date:  2014-07-03       Impact factor: 12.701

6.  Artesunate targets oral tongue squamous cell carcinoma via mitochondrial dysfunction-dependent oxidative damage and Akt/AMPK/mTOR inhibition.

Authors:  Qingfeng Xiao; Lei Yang; Hao Hu; Yue Ke
Journal:  J Bioenerg Biomembr       Date:  2020-01-21       Impact factor: 2.945

Review 7.  WNT Signaling in Cardiac and Vascular Disease.

Authors:  Sébastien Foulquier; Evangelos P Daskalopoulos; Gentian Lluri; Kevin C M Hermans; Arjun Deb; W Matthijs Blankesteijn
Journal:  Pharmacol Rev       Date:  2018-01       Impact factor: 25.468

8.  Pyrvinium Pamoate Use in a B cell Acute Lymphoblastic Leukemia Model of the Bone Tumor Microenvironment.

Authors:  Rajesh R Nair; Debbie Piktel; Quincy A Hathaway; Stephanie L Rellick; Patrick Thomas; Pushkar Saralkar; Karen H Martin; Werner J Geldenhuys; John M Hollander; Laura F Gibson
Journal:  Pharm Res       Date:  2020-01-27       Impact factor: 4.200

9.  Mitochondria as a Potential Target for the Development of Prophylactic and Therapeutic Drugs against Schistosoma mansoni Infection.

Authors:  Keith Kiplangat Talaam; Daniel Ken Inaoka; Takeshi Hatta; Daigo Tsubokawa; Naotoshi Tsuji; Minoru Wada; Hiroyuki Saimoto; Kiyoshi Kita; Shinjiro Hamano
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191

10.  Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration.

Authors:  Isao Ishii; Yasuo Harada; Tadashi Kasahara
Journal:  Front Oncol       Date:  2012-10-02       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.